Genetic neuropathology of Parkinson's disease
- PMID: 18784814
- PMCID: PMC2480564
Genetic neuropathology of Parkinson's disease
Abstract
Parkinson's disease (PD) has long been considered to be a sporadic entity, perhaps with an environmental etiology. However, recent genetic discoveries have challenged this view, as there are many families with diseases of Mendelian inheritance that clinically resemble PD. Here, we will review in detail the neuropathological data relating to familial cases of PD. We will discuss the complicated relationships between the genetically defined cases and the two key pathological events seen in PD, namely loss of dopaminergic neurons in the substantia nigra pars compacta and the formation of protein inclusions, Lewy bodies, in the neurons that survive to the end stage of the disease course. These observations will be synthesized into an overall scheme that emphasizes the two key aspects of the neuropathology as distinct events and suggest that each gene tells us something a little different about the neuropathology of PD.
Keywords: LRRK2; Parkinson's disease; neuropathology; parkin; parkinsonism; tau; α-synuclein.
Figures

Similar articles
-
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.J Neurosci. 2016 Jul 13;36(28):7415-27. doi: 10.1523/JNEUROSCI.3642-15.2016. J Neurosci. 2016. PMID: 27413152 Free PMC article.
-
What genetics tells us about the causes and mechanisms of Parkinson's disease.Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010. Physiol Rev. 2011. PMID: 22013209 Review.
-
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.Brain Res. 2007 Jun 25;1155:208-19. doi: 10.1016/j.brainres.2007.04.034. Epub 2007 Apr 19. Brain Res. 2007. PMID: 17512502
-
Neuropathology of α-synuclein in Parkinson's disease.Neuropathology. 2022 Apr;42(2):93-103. doi: 10.1111/neup.12812. Epub 2022 Mar 31. Neuropathology. 2022. PMID: 35362115 Review.
-
Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations.Am J Neurodegener Dis. 2013 Nov 29;2(4):266-75. eCollection 2013. Am J Neurodegener Dis. 2013. PMID: 24319644 Free PMC article.
Cited by
-
α-Synuclein oligomers and clinical implications for Parkinson disease.Ann Neurol. 2013 Feb;73(2):155-69. doi: 10.1002/ana.23746. Epub 2012 Dec 7. Ann Neurol. 2013. PMID: 23225525 Free PMC article. Review.
-
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471. J Parkinsons Dis. 2019. PMID: 30400107 Free PMC article.
-
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.ASN Neuro. 2009 Apr 14;1(1):e00002. doi: 10.1042/AN20090007. ASN Neuro. 2009. PMID: 19570025 Free PMC article. Review.
-
Modification of α-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: its relevance to Parkinson disease.J Clin Biochem Nutr. 2018 May;62(3):207-212. doi: 10.3164/jcbn.18-25. Epub 2018 May 1. J Clin Biochem Nutr. 2018. PMID: 29892158 Free PMC article. Review.
-
DJ-1, PINK1, and their effects on mitochondrial pathways.Mov Disord. 2010;25 Suppl 1(Suppl 1):S44-8. doi: 10.1002/mds.22713. Mov Disord. 2010. PMID: 20187230 Free PMC article. Review.
References
-
- Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497–1499. - PubMed
-
- Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry. 1998;3:462–465. - PubMed
-
- Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat. 2007;28:641–653. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous